Real-world studies have evaluated the use of anticoagulants in obese patients with
nonvalvular atrial fibrillation (NVAF), but they have been limited by sample size or the use of
diagnosis codes on claims to define obesity. This retrospective study used body weight data
of≥ 100 kg or a body mass index of≥ 30 kg/m 2 to identify elderly (aged≥ 65 years) NVAF
patients with obesity in dually enrolled Veterans Affairs and fee-for-service Medicare
patients. It evaluated the risk of stroke/systemic embolism (SE) and major bleeding (MB) in …

Background Real-world studies have evaluated the use of anticoagulants in obese patients
with nonvalvular atrial fibrillation (NVAF), but they have been limited by sample size or use
of diagnosis codes to define obesity. Methods This retrospective study used body weight
data≥ 100kg or body mass index (BMI)≥ 30 to identify NVAF patients with obesity among
dually enrolled Veterans Affairs (VA) and fee-for-service (FFS) Medicare patients. It
evaluated risk of stroke/systemic embolism (SE) and major bleeding (MB) among elderly (≥ …